Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 3/A

KERYX BIOPHARMACEUTICALS INC Form 3/A August 06, 2010 FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB 3235-0104 Number: January 31, Expires: 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> FECZKO JOSEPH M	2. Date of Event RequiringStatement(Month/Day/Year)	3. Issuer Name and Ticker or Trading Symbol KERYX BIOPHARMACEUTICALS INC [KERX]			
(Last) (First) (Middle) C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, 20TH FLOOR	07/16/2010	 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner) Owner	5. If Amendment, Date Original Filed(Month/Day/Year) 07/27/2010
		OfficerOther (give title below) (specify below)			
(Street) NEW YORK, NY 10022		(2) (p)	,	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person
(City) (State) (Zip)	Table I - N	Non-Derivat	tive Securiti	ies Be	neficially Owned
1.Title of Security (Instr. 4)	2. Amount o Beneficially (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nat Owne (Instr	*
Common Stock (Restricted)	5,000 <u>(1)</u>		D	Â	
Reminder: Report on a separate line for ea	ach class of securities benefic	^{ially} S	EC 1473 (7-02	2)	

owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
Security (Instr. 4)	Expiration Date (Month/Day/Year)	Securities Underlying Derivative Security	Conversion or Exercise	- · · · · I	Beneficial Ownership
(msu. i)		Derivative becamy	of Excicise	1 01111 01	Ownership

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 3/A

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	(Instr. 5)
Stock Options (Right to Buy)	07/16/2011(2)	07/16/2020	Common Stock	50,000	\$ 3.7	D	Â

Reporting Owners

Reporting Owner Name / Address		Relationships				
		Director	10% Owner	Officer	Other	
FECZKO JOSEPH M C/O KERYX BIOPHARMACEUTICALS, II 750 LEXINGTON AVENUE, 20TH FLOOR NEW YORK, NY 10022		ÂX	Â	Â	Â	
Signatures						
/s/ James F. Oliviero, Attorney-in-fact	08/06/2010					
**Signature of Reporting Person	Date					
E-mlandler of Deenser						

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The shares of restricted stock vest as follows: 1/3 of each on July 16, 2011, July 16, 2012, and July 16, 2013.

(2) The options vest as follows: 16,667 on July 16, 2011; 16,667 on July 16, 2012; and 16,666 on July 16, 2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.